# A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy

> **NCT01589432** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 39 (actual)

## Conditions studied

- Diabetic Neuropathic Pain

## Interventions

- **DRUG:** ABT-639
- **DRUG:** Placebo
- **DRUG:** Lidocaine

## Key facts

- **NCT ID:** NCT01589432
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589432, "A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01589432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*